Carnegie acted as joint global co-ordinator and joint book-runner in the directed new share issue of 6.1 million new shares at a price of SEK 22.30 per share. BioInvent International AB, listed on the NASDAQ OMX Stockholm, is a research-based pharmaceutical company that focuses on developing antibody drugs. June, 2011.
Healthcare
Directed new share issue in BioInvent International (SE) — SEK 136 million
June 2011